A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

  • STATUS
    Recruiting
  • End date
    Jun 30, 2024
  • participants needed
    210
  • sponsor
    National Cancer Institute (NCI)
Updated on 25 October 2022
platelet count
cancer
amylase
anticonvulsants
lipase
MRI
BRAF
neutrophil count
tumor cells
complete resection
temozolomide
astrocytoma
anaplastic astrocytoma
astrocytoma, anaplastic
dipg
diffuse intrinsic pontine glioma

Summary

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG.

Description

PRIMARY OBJECTIVES:

I. To define toxicities and estimate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of selinexor administered as an oral formulation in combination with standard of care radiation therapy (RT), to pediatric patients with newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). (Dose-finding phase/phase I) II. To estimate the event-free survival (EFS) distribution for diffuse midline glioma (DMG)/HGG patients and overall survival (OS) distribution for DIPG patients associated with selinexor plus RT, followed by selinexor in patients with newly diagnosed HGG (H3 K27M mutant DMG or H3 K27-wild type HGG) or DIPG, and to compare those outcomes to historical controls. (Efficacy phase/phase II)

EXPLORATORY OBJECTIVE:

I. To bank tumor specimens and body fluids (blood and cerebrospinal fluid) for future studies.

OUTLINE: This is a phase I dose-escalation study of selinexor followed by a phase II study.

CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor orally (PO) on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a magnetic resonance imaging (MRI) and may undergo a biopsy during screening.

MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up.

After completion of study treatment, patients are followed every 3 months for year 1 (i.e., 3, 6, 9, 12 months), then every 6 months for years 2-3 (i.e., 18, 24, 30, 36 months), and finally once yearly for years 4-5 of this study.

Details
Condition Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Glioblastoma, Not Otherwise Specified, Malignant Glioma
Treatment radiation therapy, biopsy, magnetic resonance imaging, Selinexor
Clinical Study IdentifierNCT05099003
SponsorNational Cancer Institute (NCI)
Last Modified on25 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

STEP 0: Patients must be >= 12 months and =< 21 years of age at the time of enrollment on Step 0
Please note
This age range includes pre-screening for all HGG patients. Individual treatment protocols may have different age criteria
Non-DIPG patients with tumors that do not harbor an H3K27M-mutation and are >= 18 years of age will not be eligible to enroll on ACNS1821 (Step 1)
STEP 0: Patient is suspected of having localized, newly diagnosed HGG, excluding
metastatic disease, OR patient has an institutional diagnosis of DIPG
STEP 1: Patients must be >= 12 months and =< 21 years of age at the time of enrollment
STEP 1: Patients must have newly-diagnosed DIPG or HGG (including DMG)
For patients with non-pontine tumors: Patient and/or their parents or legal guardians have signed informed consent for eligibility screening on APEC14B1 Part A
STEP 1: Stratum DMG (with H3 K27M mutation)
For patients with DIPG: Patient and/or their parents or legal guardians have signed informed consent for ACNS1821
STEP 0
Note: Patients need not have either measurable or evaluable disease, i.e., DMG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment. For rare H3 K27M-mutant HGG in non-midline structures (e.g., cerebral hemispheres), these patients will be considered part of Stratum DMG
For patients with non-pontine tumors only, the specimens obtained at the time of diagnostic biopsy or surgery must be submitted through APEC14B1 ASAP, preferably within 5 calendar days of definitive surgery
STEP 1: Stratum HGG (without H3 K27M mutation)
Patients with newly-diagnosed typical DIPG, defined as tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons on at least 1 axial T2 weighted image, are eligible. No histologic confirmation is required
Please note
Patients with pontine tumors that do not meet radiographic criteria for typical DIPG (e.g., focal tumors or those involving less than 2/3 of the pontine cross-sectional area with or without extrapontine extension) are eligible if the tumors are biopsied and proven to be high-grade gliomas (such as anaplastic astrocytoma, glioblastoma, high-grade glioma not otherwise specified [NOS], and/or H3 K27M-mutant) by institutional diagnosis
Patients need not have either measurable or evaluable disease, i.e., HGG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment
STEP 1: Patients must have a performance status corresponding to Eastern Cooperative
Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16
Patients must have newly-diagnosed non-pontine H3 K27M-mutant HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
years of age and Lansky for patients =<16 years of age. Patients who are
unable to walk because of paralysis, but who are up in a wheelchair, will be
considered ambulatory for the purpose of assessing the performance score
Patients must have newly-diagnosed non-pontine H3 K27M-wild type HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
Patients who fall in this category and who are >= 18 years of age are not eligible due to another standard-of-care regimen (radiation/temozolomide) that is available
Age / Maximum Serum Creatinine (mg/dL)
to < 2 years / male: 0.6; female: 0.6
to < 6 years / male: 0.8; female: 0.8
to < 10 years / male: 1; female: 1
STEP 1: Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to step 1 enrollment)
to < 13 years / male: 1.2; female: 1.2
STEP 1: Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to step 1 enrollment)
to < 16 years / male: 1.5; female: 1.4
STEP 1: Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to step 1 enrollment)
>= 16 years / male: 1.7; female: 1.4
STEP 1: Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to step 1 enrollment) or
STEP 1: Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
A serum creatinine based on age/gender as follows (within 7 days prior to step 1
enrollment)
STEP 1: Serum amylase =< 1.5 x ULN
STEP 1: Serum lipase =< 1.5 x ULN
For patients who have a biopsy followed by resection, the date of resection will be
considered the date of definitive diagnostic surgery. If a biopsy only was performed, the
biopsy date will be considered the date of definitive diagnostic surgery
STEP 0
STEP 1: Serum glutamate pyruvate transaminase (SGPT) (alanine
aminotransferase [ALT]) =< 135 U/L. For the purpose of this study, the ULN
for SGPT is 45 U/L
STEP 1: No evidence of dyspnea at rest, no exercise intolerance, and a pulse
STEP 1: Stratum DIPG
oximetry > 94% if there is clinical indication for determination
STEP 1: Patients with seizure disorder may be enrolled if on anticonvulsants
and well controlled
STEP 1: Patients must be enrolled and protocol therapy must begin no later
than 31 days after the date of radiographic diagnosis (in the case of
non-biopsied DIPG patients only) or definitive surgery, whichever is the
later date (Day 0)

Exclusion Criteria

STEP 1: Patients must not have received any prior therapy for their central nervous
system (CNS) malignancy except for surgery and steroid medications
STEP 1: Patients who are currently receiving another investigational drug are not
eligible
STEP 1: Patients who are currently receiving other anti-cancer agents are not
eligible
STEP 1: Patients with grade > 1 extrapyramidal movement disorder
STEP 1: Patients >=18 years of age who have H3 K27M-wild type HGG
STEP 1: Patients who have an uncontrolled infection
STEP 1: Patients with metastatic disease are not eligible; MRI of spine with and
STEP 1: Patients who have received a prior solid organ transplantation
without contrast must be performed if metastatic disease is suspected by the treating
physician
STEP 1: Patients with known macular degeneration, uncontrolled glaucoma, or cataracts
STEP 1: Patients with gliomatosis cerebri type 1 or 2 are not eligible, with the
exception of H3 K27M-mutant bithalamic tumors
STEP 1: Patients who are not able to receive protocol specified radiation therapy
STEP 1
Female patients who are pregnant are ineligible since there is yet no available
information regarding human fetal or teratogenic toxicities
Lactating females are not eligible unless they have agreed not to breastfeed
their infants. It is not known whether selinexor is excreted in human milk
Female patients of childbearing potential are not eligible unless a negative
pregnancy test result has been obtained
Sexually active patients of reproductive potential are not eligible unless they
have agreed to use two effective methods of birth control (including a medically
accepted barrier method of contraception, e.g., male or female condom) for the
duration of their study participation and for 90 days after the last dose of
selinexor. Abstinence is an acceptable method of birth control
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note